Iberdomide
Zenbexus · Cereblon E3 ligase modulator (CELMoD)
2026 first-in-class CELMoD; no attributable lesion (renal impairment 11% vs 8% on the comparator arm) but exposure rises 1.8x below eGFR 30 off dialysis.
HIF-2α inhibitor (investigational)
· CASD
HIF-2α inhibitor (investigational) · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An investigational next-generation HIF-2α inhibitor for clear-cell RCC, with class-based anemia/edema effects under study.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Renal-specific data are not established. By analogy to the first-in-class HIF-2α inhibitor belzutifan, expected on-target effects include anemia (belzutifan: ~27-90% across trials) and hypoxia, plus possible fluid retention/edema; these are class effects rather than direct nephron injury. No casdatifan-specific renal incidence is published.Source: McKay et al., Am Soc Clin Oncol Educ Book 2025
Renal onset is not established; class anemia/hypoxia effects emerge during ongoing therapy.
Distilled from: “Not established; class anemia/hypoxia effects emerge during ongoing therapy.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Oral, potent, selective hypoxia-inducible factor-2α (HIF-2α) inhibitor that allosterically prevents HIF-2α/ARNT (HIF-1β) heterodimerization. HIF-2α is a key oncogenic driver in VHL-deficient clear-cell renal cell carcinoma (ccRCC); blocking it suppresses VEGF-, cyclin-D1- and EPO-driven programs. In development (ARC-20 platform; phase 3 with cabozantinib, NCT07011719); not yet approved.
Vasculature / Endothelium
Glomerular & peritubular capillaries
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 1 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
1 report is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.
Reported with a death outcome
too few reports to express as a share
Reported with hospitalization
too few reports to express as a share
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
No organ-classified adverse-event terms among this agent's top reports.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Casdatifan sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Zenbexus · Cereblon E3 ligase modulator (CELMoD)
2026 first-in-class CELMoD; no attributable lesion (renal impairment 11% vs 8% on the comparator arm) but exposure rises 1.8x below eGFR 30 off dialysis.
Modeyso · Imipridone (ONC201; DRD2/ClpP)
2025 imipridone for H3 K27M glioma; renally well tolerated — QT prolongation, not nephrotoxicity, is the safety focus.
Welireg · HIF-2α inhibitor
Anemia/hypoxia; emerging renal profile in VHL/RCC.
Lymphir · Immunotoxin (IL-2–diphtheria)
Capillary-leak syndrome → prerenal AKI.
Etcamah · Oral selective estrogen-receptor degrader (SERD)
2026 oral SERD switched in at ESR1-mutation emergence, given with a CDK4/6 inhibitor; no attributable renal lesion (creatinine rose less often than on the comparator) — the boxed warning is QTc, so electrolytes matter.
Veppanu · PROTAC estrogen-receptor degrader
2026 first PROTAC ER degrader; no meaningful intrinsic renal signal.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.